NCT02357797View on ClinicalTrials.gov

Adjunctive Vortioxetine in Schizophrenia

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 1, 2023

Study Completion Date

June 1, 2024

Conditions
SchizophreniaNegative Symptoms
Interventions
DRUG

Vortioxetine

OTHER

Placebo

Trial Locations (3)

11004

The Zucker Hillside Hospital, Glen Oaks

33319

Henderson Behavioral Health, Lauderdale Lakes

49503

Cherry Health, Grand Rapids

Sponsors

Lead Sponsor

Northwell Health

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Northwell Health

OTHER

NCT02357797 - Adjunctive Vortioxetine in Schizophrenia | Biotech Hunter | Biotech Hunter